|
1
|
Takahashi S: Current findings for
recurring mutations in acute myeloid leukemia. J Hematol Oncol.
4:362011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mardis ER, Ding L, Dooling DJ, et al:
Recurring mutations found by sequencing an acute myeloid leukemia
genome. N Engl J Med. 361:1058–1066. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ley TJ, Ding L, Walter MJ, et al: DNMT3A
mutations in acute myeloid leukemia. N Engl J Med. 363:2424–2433.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Figueroa ME, Abdel-Wahab O, Lu C, et al:
Leukemic IDH1 and IDH2 mutations result in a hypermethylation
phenotype, disrupt TET2 function, and impair hematopoietic
differentiation. Cancer Cell. 18:553–567. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yan XJ, Xu J, Gu ZH, et al: Exome
sequencing identifies somatic mutations of DNA methyltransferase
gene DNMT3A in acute monocytic leukemia. Nat Genet. 43:309–315.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Delhommeau F, Dupont S, Della Valle V, et
al: Mutation in TET2 in myeloid cancers. N Engl J Med.
360:2289–2301. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Metzeler KH, Maharry K, Radmacher MD, et
al: TET2 mutations improve the new European LeukemiaNet risk
classification of acute myeloid leukemia: a Cancer and Leukemia
Group B study. J Clin Oncol. 29:1373–1381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Delhommeau F, Jeziorowska D, Marzac C and
Casadevall N: Molecular aspects of myeloproliferative neoplasms.
Int J Hematol. 91:165–173. 2010. View Article : Google Scholar
|
|
9
|
Ko M, Huang Y, Jankowska AM, et al:
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with
mutant TET2. Nature. 468:839–843. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen Q, Chen Y, Bian C, Fujiki R and Yu X:
TET2 promotes histone O-GlcNAcylation during gene
transcription. Nature. 493:561–564. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Boissel N, Nibourel O, Renneville A, et
al: Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1
and 2 mutations in acute myeloid leukemia: a study by the Acute
Leukemia French Association group. J Clin Oncol. 28:3717–3723.
2010. View Article : Google Scholar
|
|
12
|
Schnittger S, Haferlach C, Ulke M,
Alpermann T, Kern W and Haferlach T: IDH1 mutations are detected in
6.6% of 1414 AML patients and are associated with intermediate risk
karyotype and unfavorable prognosis in adults younger than 60 years
and unmutated NPM1 status. Blood. 116:5486–5496. 2010.
|
|
13
|
Reitman ZJ and Yan H: Isocitrate
dehydrogenase 1 and 2 mutations in cancer: alterations at a
crossroads of cellular metabolism. J Natl Cancer Inst. 102:932–941.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Duncan CG, Barwick BG, Jin G, et al: A
heterozygous IDH1R132H/WT mutation induces genome-wide alterations
in DNA methylation. Genome Res. 22:2339–2355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Esteller M: Epigenetics in cancer. N Engl
J Med. 358:1148–1159. 2008. View Article : Google Scholar
|
|
16
|
Wheeler DA, Srinivasan M, Egholm M, et al:
The complete genome of an individual by massively parallel DNA
sequencing. Nature. 452:872–876. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee SW, Cho YS, Na JM, et al: ASXL1
represses retinoic acid receptor-mediated transcription through
associating with HP1 and LSD1. J Biol Chem. 285:18–29. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang J, Hevi S, Kurash JK, et al: The
lysine demethylase LSD1 (KDM1) is required for maintenance of
global DNA methylation. Nat Genet. 41:125–129. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gelsi-Boyer V, Trouplin V, Adelaide J, et
al: Mutations of polycomb-associated gene ASXL1 in myelodysplastic
syndromes and chronic myelomonocytic leukaemia. Br J Haematol.
145:788–800. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Abdel-Wahab O, Manshouri T, Patel J, et
al: Genetic analysis of transforming events that convert chronic
myeloproliferative neoplasms to leukemias. Cancer Res. 70:447–452.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chou WC, Huang HH, Hou HA, et al: Distinct
clinical and biological features of de novo acute myeloid leukemia
with additional sex comb-like 1 (ASXL1) mutations. Blood.
116:4086–4094. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fisher CL, Pineault N, Brookes C, et al:
Loss-of-function additional sex combs like 1 mutations disrupt
hematopoiesis but do not cause severe myelodysplasia or leukemia.
Blood. 115:38–46. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tiu RV, Visconte V, Traina F, Schwandt A
and Maciejewski JP: Updates in cytogenetics and molecular markers
in MDS. Curr Hematol Malig Rep. 6:126–135. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nikoloski G, Langemeijer SM, Kuiper RP, et
al: Somatic mutations of the histone methyltransferase gene EZH2 in
myelodysplastic syndromes. Nat Genet. 42:665–667. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ernst T, Chase AJ, Score J, et al:
Inactivating mutations of the histone methyltransferase gene EZH2
in myeloid disorders. Nat Genet. 42:722–726. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Makishima H, Jankowska AM, Tiu RV, et al:
Novel homo- and hemizygous mutations in EZH2 in myeloid
malignancies. Leukemia. 24:1799–1804. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chase A and Cross NC: Aberrations of EZH2
in cancer. Clin Cancer Res. 17:2613–2618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jankowska AM, Makishima H, Tiu RV, et al:
Mutational spectrum analysis of chronic myelomonocytic leukemia
includes genes associated with epigenetic regulation: UTX, EZH2,
and DNMT3A. Blood. 118:3932–3941. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sauvageau M and Sauvageau G: Polycomb
group proteins: multi-faceted regulators of somatic stem cells and
cancer. Cell Stem Cell. 7:299–313. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Haaften G, Dalgliesh GL, Davies H, et
al: Somatic mutations of the histone H3K27 demethylase gene UTX in
human cancer. Nat Genet. 41:521–523. 2009.PubMed/NCBI
|
|
31
|
Basecke J, Whelan JT, Griesinger F and
Bertrand FE: The MLL partial tandem duplication in acute myeloid
leukaemia. Br J Haematol. 135:438–449. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu BD, Hess JL, Horning SE, Brown GA and
Korsmeyer SJ: Altered Hox expression and segmental identity in
Mll-mutant mice. Nature. 378:505–508. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Milne TA, Briggs SD, Brock HW, et al: MLL
targets SET domain methyltransferase activity to Hox gene
promoters. Mol Cell. 10:1107–1117. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dorrance AM, Liu S, Yuan W, et al: Mll
partial tandem duplication induces aberrant Hox expression in vivo
via specific epigenetic alterations. J Clin Invest. 116:2707–2716.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Whitman SP, Hackanson B, Liyanarachchi S,
et al: DNA hypermethylation and epigenetic silencing of the tumor
suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL
partial tandem duplication. Blood. 112:2013–2016. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Munoz L, Nomdedeu JF, Villamor N, et al:
Acute myeloid leukemia with MLL rearrangements: clinicobiological
features, prognostic impact and value of flow cytometry in the
detection of residual leukemic cells. Leukemia. 17:76–82. 2003.
View Article : Google Scholar
|
|
37
|
Lugthart S, van Drunen E, van Norden Y, et
al: High EVI1 levels predict adverse outcome in acute myeloid
leukemia: prevalence of EVI1 overexpression and chromosome 3q26
abnormalities underestimated. Blood. 111:4329–4337. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Groschel S, Lugthart S, Schlenk RF, et al:
High EVI1 expression predicts outcome in younger adult patients
with acute myeloid leukemia and is associated with distinct
cytogenetic abnormalities. J Clin Oncol. 28:2101–2107
|
|
39
|
Delwel R, Funabiki T, Kreider BL,
Morishita K and Ihle JN: Four of the seven zinc fingers of the
Evi-1 myeloid-transforming gene are required for sequence-specific
binding to GA(C/T)AAGA(T/C)AAGATAA. Mol Cell Biol. 13:4291–4300.
1993.PubMed/NCBI
|
|
40
|
Matsugi T, Kreider BL, Delwel R, Cleveland
JL, Askew DS and Ihle JN: The Evi-1 zinc finger myeloid
transforming protein binds to genomic fragments containing (GATA)n
sequences. Oncogene. 11:191–198. 1995.PubMed/NCBI
|
|
41
|
Perkins AS, Fishel R, Jenkins NA and
Copeland NG: Evi-1, a murine zinc finger proto-oncogene, encodes a
sequence-specific DNA-binding protein. Mol Cell Biol. 11:2665–2674.
1991.PubMed/NCBI
|
|
42
|
Lugthart S, Figueroa ME, Bindels E, et al:
Aberrant DNA hypermethylation signature in acute myeloid leukemia
directed by EVI1. Blood. 117:234–241. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Boultwood J and Wainscoat JS: Gene
silencing by DNA methylation in haematological malignancies. Br J
Haematol. 138:3–11. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Figueroa ME, Lugthart S, Li Y, et al: DNA
methylation signatures identify biologically distinct subtypes in
acute myeloid leukemia. Cancer Cell. 17:13–27. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mueller BU, Pabst T, Osato M, et al:
Heterozygous PU.1 mutations are associated with acute myeloid
leukemia. Blood. 100:998–1007. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Vegesna V, Takeuchi S, Hofmann WK, et al:
C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in
381 samples of hematopoietic and solid malignancies. Leuk Res.
26:451–457. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lamandin C, Sagot C, Roumier C, et al: Are
PU.1 mutations frequent genetic events in acute myeloid leukemia
(AML)? Blood. 100:4680–4681. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
DeKoter RP and Singh H: Regulation of B
lymphocyte and macrophage development by graded expression of PU.1.
Science. 288:1439–1441. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rosenbauer F, Wagner K, Kutok JL, et al:
Acute myeloid leukemia induced by graded reduction of a
lineage-specific transcription factor, PU.1. Nat Genet. 36:624–630.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
50
|
Steidl U, Rosenbauer F, Verhaak RG, et al:
Essential role of Jun family transcription factors in PU.1
knockdown-induced leukemic stem cells. Nat Genet. 38:1269–1277.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
51
|
Suzuki M, Yamada T, Kihara-Negishi F, et
al: Site-specific DNA methylation by a complex of PU.1 and
Dnmt3a/b. Oncogene. 25:2477–2488. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Imoto A, Okada M, Okazaki T, Kitasato H,
Harigae H and Takahashi S: Metallothionein-1 isoforms and vimentin
are direct PU.1 downstream target genes in leukemia cells. J Biol
Chem. 285:10300–10309. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Suzuki S, Nakano H and Takahashi S:
Epigenetic regulation of the metallothionein-1A promoter by PU.1
during differentiation of THP-1 cells. Biochem Biophys Res Commun.
433:349–353. 2013. View Article : Google Scholar : PubMed/NCBI
|
